Researchers at the Southampton Clinical Trials Unit are set to trial a new blood test aimed at improving early detection of pancreatic cancer, one of the most difficult cancers to diagnose and treat.
The Avantect test, developed by ClearNote Health, will be evaluated through the SAFE-D study, focusing on individuals recently diagnosed with type 2 diabetes, a known risk factor. By identifying pancreatic cancer at an earlier, more treatable stage, this study could offer new hope for improving survival rates.
Learn more about the study here: